{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.13","value":"6.85"}]}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.61","value":"8.27"}]}],"title":"Cycle 1 Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Plasma decay half-life is the time measured for the plasma concentration of the drug to decrease by one half.","dispersionType":"Standard Deviation","groups":[{"description":"All participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days.","id":"OG000","title":"All Participants - Pomalidomide 5mg Daily"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"At pre-dose, 1, 2, 3, 4, 6, and 8 hours after dose on Cycle 1 Day 1, and pre-dose, 1, 2, 3, 4, 6, 8, and 24 hours after dose on Cycle 1 Day 15.","title":"Half-Life of Pomalidomide","type":"PRIMARY","unitOfMeasure":"hours"}